Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
105,841,018
-
Number of holders
-
22
-
Total 13F shares, excl. options
-
3,114,137
-
Shares change
-
+108,012
-
Total reported value, excl. options
-
$4,889,035
-
Value change
-
+$175,383
-
Put/Call ratio
-
1.6%
-
Number of buys
-
12
-
Number of sells
-
-5
-
Price
-
$1.57
Significant Holders of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) as of Q2 2023
30 filings reported holding SLS - SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share as of Q2 2023.
SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) has 22 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3,114,137 shares
of 105,841,018 outstanding shares and own 2.9% of the company stock.
Largest 10 shareholders include Alyeska Investment Group, L.P. (1,250,000 shares), VANGUARD GROUP INC (946,708 shares), BlackRock Inc. (283,368 shares), GEODE CAPITAL MANAGEMENT, LLC (188,066 shares), Equitable Holdings, Inc. (135,000 shares), STATE STREET CORP (97,129 shares), NORTHERN TRUST CORP (39,360 shares), Opus Capital Group, LLC (31,000 shares), Prosperity Financial Group, Inc. (29,800 shares), and Bank of New York Mellon Corp (20,743 shares).
This table shows the top 22 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.